Advance on the diagnostic potential of biological markers in the early detection of Alzheimer Disease

2004 ◽  
Vol 35 (3) ◽  
pp. 232-245 ◽  
Author(s):  
Barbara Borroni ◽  
Monica DiLuca ◽  
Flaminio Cattabeni ◽  
Alessandro Padovani
2010 ◽  
Vol 2010 ◽  
pp. 1-7 ◽  
Author(s):  
Hyman M. Schipper

Decreased -amyloid1-42and increased phospho-tau protein levels in the cerebrospinal fluid (CSF) are currently the most accurate chemical neurodiagnostics of sporadic Alzheimer disease (AD). A report (2007) of the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (2006) recommended that biological markers shouldnotbe currently requisitioned by primary care physicians in the routine investigation of subjects with memory complaints. Consideration for such testing should prompt patient referral to a specialist engaged in dementia evaluations or a Memory Clinic. The specialist should consider having CSF biomarkers (-amyloid1-42and phospho-tau) measured at a reputable facility in restricted cases presenting with atypical features and diagnostic confusion, but not as a routine procedure in all individuals with typical sporadic AD phenotypes. We submit that developments in the field of AD biomarker discovery since publication of the 3rd CCCDTD consensus data do not warrant revision of the 2007 recommendations.


Author(s):  
Mark Hallett

Apraxia is the inability to perform skilled and/or learned movements, not explainable on the basis of more elemental abnormalities. There are several types of apraxia of which the most commonly recognized are (1) limb kinetic apraxia, the loss of hand and finger dexterity; (2) ideomotor apraxia, deficits in pantomiming tool use and gestures with temporal and spatial errors, but with knowledge of the tasks still present; (3) ideational apraxia, the failure to carry out a series of tasks using multiple objects for an intended purpose; and (4) conceptual apraxia, loss of tool knowledge, when tools and objects are used inappropriately. Apraxia can be a feature of both frontotemporal dementia and Alzheimer disease, and even a rare presenting manifestation of both. How sensitive apraxia measures would be in early detection is not well known.


Neurology ◽  
2011 ◽  
Vol 77 (5) ◽  
pp. 453-460 ◽  
Author(s):  
N. M. Scheinin ◽  
S. Aalto ◽  
J. Kaprio ◽  
M. Koskenvuo ◽  
I. Raiha ◽  
...  

2020 ◽  
Vol 176 ◽  
pp. 763-770
Author(s):  
Randa Ben Ammar ◽  
Yassine Ben Ayed

2008 ◽  
Vol 119 (9) ◽  
pp. e123
Author(s):  
A. Fernández Nin ◽  
Y. Fernández ◽  
M.A. Bobes León ◽  
F. Lopera ◽  
Y.T. Quiroz ◽  
...  

2016 ◽  
Vol 36 (1) ◽  
pp. 55-76
Author(s):  
Al-Bokhary, M. S. ◽  
Marei, Elham. S. ◽  
Al-Debaiky, Kh. F.

Author(s):  
S. Soundarya ◽  
M.S. Sruthi ◽  
S. Sathya Bama ◽  
S. Kiruthika ◽  
J. Dhiyaneswaran

Sign in / Sign up

Export Citation Format

Share Document